RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
N/A
Synonyms :
neracorvir
Class :
Antiviral agent
Dosage Forms & Strengths
An investigational drug used for the treatment of Hepatitis B virus.
Dosage Forms & Strengths
Safety and efficacy not established
Refer adult dosing
Actions and Spectrum:
Neracovir is a antiviral agent that targets the stages of life cycle. This includes fusion inhibitors, NRTIs, NNRTIs, CCR5 antagonists, integrase inhibitors, protease inhibitors that disrupts DNA and RNA polymerase and preventing the entry of virus.
Frequency not defined
Not reported
Black box warning:
None
Contraindications/caution:
There is no specific information
Pregnancy/Lactation
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Limited data available
Pharmacokinetics:
There is no specific information
Administration:
Limited data is available
Patient information leaflet
Generic Name: neracorvir
Why do we use neracorvir?
It is an effective antiviral agent as it exhibits the anti-Hepatitis B activity.